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The HCV polymerase is an attractive target for the development of new and specific anti-HCV drugs. Herein, the characterization of the
inhibitory effect of 2′-C-Methyl-Cytidine shows that it is a potent inhibitor of both genotype 1b and 1a HCV replicon replication, both of
laboratory-optimized as well as of NS5B clinical isolates–chimera replicons. The corresponding 5′-triphosphate derivative is a potent inhibitor of
native HCV replicase isolated from replicon cells and of the recombinant genotype 1b and 1a HCV polymerase-mediated RNA synthesis.
Resistance to 2′-C-Methyl-Cytidine was mapped to amino acid substitution S282T in the NS5B coding region. Cross-resistance was observed to
2′-C-Methyl-Adenosine but not to interferon α-2a, to non-nucleoside HCV polymerase inhibitors or to R1479, a new and potent nucleoside
inhibitor of NS5B polymerase. In vitro studies mapped resistance to R1479 to amino acid substitutions S96T and S96T/N142T of the NS5B
polymerase. These mutations did not confer resistance to 2-C-Methyl-Cytidine, thus confirming the lack of cross-resistance between these two
HCV inhibitors. These data will allow the optimization of new polymerase inhibitors and their use in combination therapy.
© 2006 Elsevier Inc. All rights reserved.Keywords: Hepatitis C virus; Treatment; NS5B polymerase; Inhibitors; Drug resistance; Nucleoside analogs; Combination therapyIntroduction
Hepatitis C virus (HCV), a positive strand RNA virus, is a
member of the Hepacivirus genus, in the Flaviviridae family,
and is one of the leading causes of liver disease worldwide. It is
estimated that over 170 million individuals are infected world-
wide with HCV (Wasley and Alter, 2000). The virus has been
classified into 6 major genotypes (1–6) showing more than 30%
divergence among them. Each genotype contains a series of
more closely related subtypes which show a 20–25% divergence
in nucleotide sequences (Simmonds, 2004). Acute infectionwith
HCV develops into chronic infection in approximately 80% of
individuals, and chronic hepatitis can, in turn, progress to cir-
rhosis and hepatocellular carcinoma. The current treatment for
chronic hepatitis C is pegylated interferon α (IFN-α) in combi-⁎ Corresponding author. Fax: +1 650 354 7554.
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doi:10.1016/j.virol.2006.03.045nation with ribavirin (Fried et al., 2002; Hadziyannis et al., 2004;
Manns et al., 2001) that results in approximately 50% of a
sustained viral response (SVR) for patients infected with a
genotype 1 virus and approximately 80% SVR for patients in-
fected by genotype 2 or genotype 3 viruses. However, the treat-
ment is often poorly tolerated, limiting its use in some patients
and emphasizing the urgent need for more effective and HCV-
specific antiviral therapies.
The HCV polymerase is an essential enzyme for virus RNA
replication and represents an attractive therapeutic target. With
the advent of the HCV replicon cell culture system, there have
been extensive developments around the discovery of new HCV
polymerase inhibitors, both nucleoside (Carroll et al., 2003;
Migliaccio et al., 2003; Olsen et al., 2004) and non-nucleoside
inhibitors (Beaulieu et al., 2004a–c; Chan et al., 2004a,b;
Dhanak et al., 2002). While new HCV inhibitors have yet to be
approved for the treatment of HCV-infected individuals, HCV
polymerase inhibitor NM283, a valine ester prodrug of NM107,
2′-C-Methyl-Cytidine (2′-C-Me-C) is currently in phase II
Table 1
2′-C-Me-C is active against genotype 1b and genotype 1a HCV replicon
replication
Compound
Con1a H77b
IC50 (μM)
Renillac
IC50 (μM)
TaqMand
CC50 (μM)
WST-1e
IC50 (μM)
Renillaf
CC50 (μM)
WST-1f
2′-C-Me-C 1.1 ± 0.03 0.9 ± 0.12 >100 0.3 ± 0.03 >100
a Con1 replicon refers to genotype 1b strain Con1 stable replicon.
b H77 replicon refers to genotype 1a strain H77 stable replicon.
c Inhibition of HCV replicon encoded renilla luciferase reporter; mean IC50
value and standard error of mean determined from 354 independent
experiments.
d Inhibition of HCV replicon RNA levels; mean IC50 value and standard error
of mean determined from 36 independent experiments.
e Cell viability determined from 354 independent experiments.
f Mean IC50 and CC50 values and standard error of mean were determined
from 14 independent experiments.
350 S. Le Pogam et al. / Virology 351 (2006) 349–359clinical trials (Godofsky et al., 2004; Pierra et al., 2005).
Recently, a new potent nucleoside HCV polymerase inhibitor,
R1479 (4′-Azido-Cytidine), which has been selected for further
clinical development for the treatment of HCV infection has
been described (Klumpp et al., 2006). The high genetic
heterogeneity of HCV, due to the error-prone nature of its
RNA-dependent RNA polymerase, represents an opportunity
for the virus to evade antiviral treatment. The development of
successful therapies based on inhibitors targeting viral enzymes
requires an understanding of the nature of resistant HCV variants
likely to be selected upon treatment. This will help in the design
and selection of new inhibitors with different resistance profiles
with the aim of delaying the selection of resistant variants, thus
resulting in more efficacious therapies. Previous studies have
demonstrated the possibility of selecting HCV-resistant variants
against different antiviral agents using the HCV subgenomic
replicon system (Migliaccio et al., 2003; Nguyen et al., 2003;
Tomei et al., 2003, 2004). Here, we have used the HCV
subgenomic replicon to select and characterize HCV-resistant
variants to 2′-C-Me-C, and to R1479, two potent HCV
polymerase inhibitors. In this study, we show that unique
amino acid substitutions in the NS5B gene are responsible for
resistance to 2′-C-Me-C or to R1479. These findings confirm the
lack of cross-resistance between these polymerase inhibitors and
will help in the design of future combination therapies.
Results
2′-C-Methyl-Cytidine inhibits genotype 1b and genotype 1a
HCV replication
To determine the activity of 2′-C-Me-C (Fig. 1) on HCV
replicon replication, the inhibitor was tested using the genotype
1b strain Con1 and genotype 1a strain H77 stable HCV sub-Fig. 1. Chemical structures of (A) 2′-C-Methyl-Cytidine, (B) 2′-C-Methyl-Adenosine
(F) Thiophene-2-carboxylic acid (NNI-2).genomic replicons and was measured as a reduction of reporter
renilla luciferase levels after 72 h of treatment. 2′-C-Me-C in-
hibited both the genotype 1b strain Con1 replicon, with an IC50
value of 1.1 μM (Klumpp et al., 2006) and the genotype 1a strain
H77 replicon with an IC50 value of 0.3 μM (Table 1). No cyto-
toxicity, as measured byWST-1, was observed up to 100 μM for
genotype 1b (Klumpp et al., 2006) or for genotype 1a (Table 1).
The inhibitory activity of 2′-C-Me-C was also evaluated on
transient replicons containing the NS5B coding region from
genotype 1b and 1a clinical isolates (seeMaterials andmethods),
showing similar potency than for the laboratory-optimized Con1
and H77 replicons (Table 2).
The inhibition potency of 2′-C-Me-CTP on the RdRp activity
of recombinant NS5B proteins was confirmed using both
genotype 1b (NS5B570-BK and NS5B570-Con1) and genotype
1a (NS5B570-H77) enzymes (Table 3). Genotype 1a NS5B570-
H77 polymerase showed similar sensitivity to the compound, (C) 3′-deoxy-Cytidine, (D) R1479, (E) Benzo-1, 2, 4-thiadiazine (NNI-1), and
Table 2
2′-C-Me-C is active against genotype 1b and 1a NS5B clinical isolates
Genotype 1b NS5B 2′-C-Me-C IC50 (μM)
a
Con1 1.0 ± 0.1
Pt 1 1.0 ± 0.07
Pt 2 0.8 ± 0.17
Pt 3 0.6 ± 0.11
Pt 4 0.7 ± 0.16
Genotype 1a NS5B 2′-C-Me-C IC50 (μM)
a
H77 0.4 ± 0.03
Pt 5 0.3 ± 0.05
Pt 6 0.3 ± 0.04
Pt 7 0.3 ± 0.05
Pt 8 0.4 ± 0.07
Pt 9 0.4 ± 0.06
Pt 10 1.1 ± 0.23
Pt 11 0.65 ± 0.08
a Inhibition of transient HCV replicon RNA replication containing the NS5B
from genotype 1b or genotype 1a clinical isolates; mean IC50 values and standard
error of mean determined from at least 3 independent experiments.
Fig. 2. Additive inhibition of HCV replicon RNA by 2′-C-Me-C in combination
with IFN-α. Isobolograms of FIC (2′-C-Me-C) against FIC (IFN-α) measured at
90% endpoints as described in Materials and methods. Isobolograms were
derived from 3 independent experiments.
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termined under PI (Poly I) assay conditions, which only drive the
incorporation of cytidine monophosphate (CMP) into the RNA
product, were 3-fold to 8-fold lower than the IC50 values de-
termined under genotype 1a assay conditions, which drive the
incorporation of all four nucleotide monophosphates. This shift
in potency was consistent with a specific inhibition of CMP
incorporation by 2′-C-Me-CTP (Klumpp et al., 2006).
Additive inhibition of HCV replication by 2′-C-Me-C in
combination with IFN-α
In order to assess the activity of 2′-C-Me-C in combination
with IFN-α, in vitro combination studies were carried out as
described in Materials and methods. The fractions of the inhi-
bitory concentrations (FIC values) were derived from the calcu-
lation of 90% inhibition of the renilla luciferase reporter across
checkerboard titrations of both inhibitors after 72 h incubation
(0.04 to 10 IU/ml for IFN-α and 0.04 to 10 μM for 2′-C-Me-C).
The combination index (FICA + FICB) for 2′-C-Me-C in com-
bination with IFN-α was calculated to be between 0.5 and 1
(additive line), indicating that this combination inhibits the
replicon RNA replication in an additive manner (Fig. 2). The
data were also examined using the Pritchard and Shipman's 3-D
model (MacSynergy II) (Prichard and Shipman, 1990), whereTable 3
2′-C-Me-CTP inhibits the RdRp activity of genotype 1a and genotype 1b
recombinant NS5B enzymes
Polymerase Mean IC50 Values (μM)
Genotype cIRES Poly I
NS5B570-BK 1b 0.15 ± 0.04 0.04 ± 0.01
NS5B570-Con1 1b 0.16 ± 0.05 0.06 ± 0.02
NS5B570-H77 1a 0.25 ± 0.05 0.03 ± 0.01
The IC50 values and standard deviation were determined from at least 3
independent experiments under either genotype 1a or PI assay conditions, as
described in Materials and methods.the nature of the combination is examined across the whole
range of inhibitory concentrations used (data not shown). Con-
sistent results were obtained using both methods.
2′-C-Me-C can clear the HCV replicon RNA
To determine the kinetics of the subgenomic HCV replicon
inhibition by 2′-C-Me-C, HCV replicon cells were cultured in
the presence of 8 μM of inhibitor for 13 days and in the absence
of neomycin selection (replicon clearance phase) (Fig. 3). Dur-
ing this phase, Huh-7 cells were able to proliferate even in
the absence of active replicon replication. During the rebound
phase, the inhibitor was removed, and cells were cultured for a
further 15 days in culture medium containing 0.25 mg/ml of
neomycin. HCV RNA levels were monitored every 3 days as
described in Materials and methods and remained constant
throughout the replicon clearance phase in the untreated cells.
During the rebound phase, the addition of neomycin had no
effect on the level of HCV RNA. In the presence of 8 μM of
inhibitor and after 10 days, the HCV RNA level dropped a
maximum of 3.8 logs. After 13 days, the HCV RNA had aFig. 3. 2′-C-Me-C is able to clear the HCV subgenomic replicon. HCV replicon
cells were treated with 8 μMof 2′-C-Me-C in the absence of neomycin selection.
After 13 days of passaging (replicon clearance phase), the inhibitor was removed,
and the neomycin was added back in the culture medium (rebound phase). Levels
of HCV RNA in treated cells (▴) are expressed as a log change compared to the
HCV RNA level in untreated cells (♦) at day 0.
Table 4
Characterization of replicon clones after selection with 2′-C-Me-C
Cellular
clones
IC50 (μM)
a NS5B
mutations
2′-C-Me-C 2′-C-Me-A NNI-1 IFN-α
Untreated 0.8 ± 0.1 0.2 3.5 ± 0.4 0.56 –
1 >33 NDb NDb NDb S282T
5 >33 4.4 4.3 1.7 K81N, S282T
9 1.1 0.5 1.7 1.2 T181T/P
10 21.4c 4.0 3.0 1.3 S282T, M573R
a Inhibition of HCV replicon RNA determined from duplicates by quantitative
kinetic PCR.
b ND, not determined.
c IC50 value is approximate as curve did not reach 100% inhibition.
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RNA observed after day 8 could be due to the detection of
residual RNAs that are not fully replication competent or could
be a reflection of the presence of small levels of replicons able to
replicate in the presence of inhibitor. However, the HCV
subgenomic RNA replication was inhibited to levels that were
not sufficient enough to allow the survival of the cells even in the
presence of low concentrations of neomycin (0.25 mg/ml).
Selection and characterization of replicons resistant to 2′-C-Me-C
Replicon cellular clones resistant to 2′-C-Me-C were obtained
after long-term culture in the presence of increasing concentra-
tions of 2′-C-Me-C starting at 6 μM and up to 24 μM. All clones
contained similar levels of HCV replicon RNA as determined by
quantitative kinetic PCR (data not shown). Four cellular clones
were further characterized by direct sequencing of PCR products
spanning the entire NS3 to NS5B regions, as well as by deter-
mining their susceptibility to different classes of HCV inhibitors.
While the mean 2′-C-Me-C IC50 value for the untreated cells was
0.8 ± 0.1 μM and for clone 9 was 1.1 μM, three replicon cellular
clones (clones 1, 5, and 10) showed reduced susceptibility to 2′-C-
Me-C (Table 4). Cross-resistance was observed to 2′-C-Me-A
(Fig. 1, Table 4),whereas no cross-resistancewas observed to non-
nucleoside inhibitor benzo-1, 2, 4-thiadiazine derivative (NNI-1)
(Fig. 1, Table 4) or to IFN-α (Table 4). Sequencing analysis of theFig. 4. Inhibition of WTand S282T replicases by 2′-C-Me-CTP and 3′-dCTP. (A) Det
1.25 μl; c, 2.5 μl. (B) Inhibitory potency of 2′-C-Me-CTP and 3′-dCTP on WT and S
are shown. RNA synthesis activities of WT and S282T replicases were tested in theentire non-structural region, spanningNS3 toNS5B revealed only
one common mutation in the NS5B polymerase gene at position
282, changing a serine to a threonine in all three resistant clones
and not in sensitive cells. Clones 5 and 10 had one additional mu-
tation, either K81N orM573R, respectively (Table 4). Sequencing
analysis of 26 molecular clones of replicon cellular clone 10
showed that mutations S282T and M573R coexisted in all
genomes (data not shown).
To confirm that the observed resistant phenotype was not due
to a cellular effect, cytoplasmic replicase complexes (CRCs) from
cells carrying wild type (WT) or S282T replicon obtained as
described in Materials and methods were isolated and used to
measure the inhibition of RNA synthesis activity by 2′-C-Me-
CTP. As a control, the relative expression levels of NS5B in the
WT or S282T CRCs were determined by Western blotting using
recombinant NS5B570-BK as a reference. The NS5B levels in
WT and S282T CRCs were derived from the NS5B band
volumes of loading 0.625 μl of CRC, which were within the
linear range of band volumes of recombinant NS5B570-BK
titrations (Fig. 4A lane a, and data not shown). The NS5B protein
levels in WT and S282T replicase complexes were 19.3 and
18.4 ng/μl (5 × 105 cells equivalent) of membrane fraction
respectively, suggesting that S282T mutation does not cause a
measurable change in the overall stability and steady-state level
of the NS5B protein in stably transfected replicon cells. Under the
in vitro replicase assay conditions, the WT and S282T replicases
showed similar time course kinetics with RNA product formation
increasing linearly with reaction time up to 90 and 120 min,
respectively (data not shown). Therefore, 90-min reaction time
was chosen as the condition for measuring inhibitory effects of
compounds on both replicases. S282T replicase had a reduced
susceptibility to the inhibition by 2′-C-Me-CTP with a mean IC50
value of 12.1 ± 4.6 μM, which is 60-fold higher than that of the
WT replicase (0.20 ± 0.17 μM). However, both WT and S282T
replicases showed similar sensitivity to 3′-dCTP (Fig. 1, Fig. 4B
and Table 5) and to R1479-TP (Klumpp et al., 2006). These
results showed that resistance to 2′-C-Me-C was indeed due to a
viral component and likely correlated with the presence of the
S282T mutation in the polymerase gene.ection of NS5B inWTand S282T CRCs. Volume of CRCs loaded: a, 0.625 μl; b,
282T replicases. Representative gels from at least two independent experiments
presence of the inhibitors at the concentrations indicated.
Table 5
Inhibition of WT and S282T HCV replicases by 2′-C-Me-CTP and 3′-dCTP
Replicate complex
Native HCV replicase IC50 (μM)
2′-C-Me-CTP 3′-dCTP
WT 0.2 ± 0.17 0.78 ± 0.5
S282T 12.1 ± 4.6 0.76 ± 0.1
The mean IC50 values and standard deviation were determined from at least 2
independent experiments.
Fig. 5. Mutation S282T confers resistance to 2′-C-Me-C and to 2′-C-Me-(A)
Relative reduction of luciferase activity in cured Huh-7 cells transiently
transfected with WT (filled symbols) or S282T mutant (open symbols) HCV
replicon RNAs. Cells were incubated for 72 h with 2′-C-Me-C (△) or with 2′-C-
Me-A (∘). Data points are mean values, and error bars are SEM values
calculated from 10 independent experiments.
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polymerase
To confirm the role of the NS5B amino acid residue S282 in
resistance to 2′-C-Me-C, mutation S282Twas engineered into the
WT transient genotype 1b replicon by site directed mutagenesis.
RepliconRNAswere transiently transfected into curedHuh-7 cells
and their replication levels and susceptibility to 2′-C-Me-C, 2′-C-
Me-A and to a thiophene carboxylic acid derivative (non-
nucleoside inhibitor NNI-2, Fig. 1) were determined. The tran-
sient replication capacity of S282T mutant was impaired, with a
replication capacity of 22% compared to theWT transient replicon
(Table 6) as previously described (Migliaccio et al., 2003). Mu-
tation S282T conferred resistance to 2′-C-Me-C, with a 30-fold
IC50 shift (Fig. 5, Table 6), showing cross-resistance to 2′-C-Me-
A, as previously described (Migliaccio et al., 2003). Importantly, it
did not confer resistance to R1479 (Klumpp et al., 2006) or to
NNI-2 (Table 6).
To determine the role of amino acid substitution M573R,
single mutant M573R and double mutant S282T/M573R were
engineered in the Con1 transient replicon. Single mutantM573R
did not confer resistance to 2′-C-Me-C or to other HCV poly-
merase inhibitors nor did it confer a significant replication ad-
vantage to the wild type or S282T replicon in the absence or
presence of 2′-C-Me-C (Table 6).
To correlate the decrease in inhibition potency of 2′-C-Me-C
on the resistant replicon containing the S282T mutation in the
NS5B polymerase, the single mutant S282T recombinant en-
zyme was engineered in the NS5B570-Con1 backbone and
tested in the polymerase assay. The inhibitory potency of 2′-C-
Me-CTP onNS5B570-Con1-S282Twas reduced by 111-fold. InTable 6
S282T confers resistance to 2′-C-Me-C and 2′-C-Me-A and not to R1479 or to
thiophene-2-carboxylic acid derivative (NNI-2)
Transient
replicon
Replication
levela
IC50 (μM)
b
2′-C-Me-C 2′-C-Me-A R1479 NNI-2
WT 1 1.05 ± 0.09 0.1 ± 0.01 1.96 ± 0.14 0.3 ± 0.03
S282T 0.22 28.5 ± 2.95 1.8 ± 0.28 0.5 ± 0.10 0.2 ± 0.04
M573R 1.15 2.1 ± 0.25 0.2 ± 0.03 NDc 0.4 ± 0.03
S282T/
M573R
0.26 55.3 ± 16.43d 3.4 ± 0.66 NDc 0.3 ± 0.04
a Replication level of mutant transient replicons are expressed compared to the
WT transient replicon in the absence of inhibitor.
b The mean IC50 values and standard error of mean were determined from at
least 3 independent experiments.
c ND, not determined.
d The mean IC50 value is approximate as curves did not reach 100%
inhibition.contrast, it did not confer resistance to 3′-dCTP (Table 7) or to
R1479-TP (Klumpp et al., 2006), confirming the specific role of
S282T mutation in resistance to 2′-C-Me-C. Kinetic analysis of
NS5B570-Con1-S282T showed a 2-fold increase in Vmax
app and a
2-fold decrease in Km
app (CTP) compared to NS5B570-Con1,
leading to a 4-fold increase in enzyme efficiency (Vmax
app /Km
app
(CTP)) of the S282T mutant over wild type (data not shown).
Selection and characterization of replicons resistant to R1479
confirms lack of cross resistance with 2′-C-Me-C
We have recently selected replicons resistant to R1479
through the sequential passage of cell line 2209-23 in the pres-
ence of increasing concentrations of R1479, as detailed in Ma-
terials and methods. Replicon cells selected in the presence of
60 μMR1479 showed a decrease in sensitivity to the inhibitor of
more than 50-fold (mean IC50 values ranged from 20.8 ± 2.3 μM
to 56 ± 0.8 μM) compared to the untreated replicon cells (Table
8). Direct sequencing of PCR products from replicon cells
isolated after 37, 39, 41, and 50 passages in the presence of
60 μM of R1479 showed amino acid substitutions at residues 96
and 142 of the polymerase, which were not present in untreated
cells from passage 41 (as demonstrated by direct sequencing of
PCR products as well as by sequencing of 10 molecular clones).Table 7
Inhibition of WT and S282T mutant HCV polymerase activities by 2′-C-Me-
CTP and 3′-dCTP
Enzyme IC50 (μM)
2′-C-Me-CTP 3′-dCTP
NS5B570-BK 0.18 ± 0.06 0.17 ± 0.05
NS5B570-Con1 0.09 ± 0.02 0.32 ± 0.04
NS5B570-Con1-S282T 10.0 ± 0.60 0.55 ± 0.10
The IC50 values and standard deviation were determined under genotype 1b
assay conditions, as described in Materials and methods from at least two
independent experiments.
Table 8
Characterization of replicon cells after selection with R1479
Passage number Amino acid substitution in NS5B IC50 (μM) R1479
a
Untreated p41 –b 0.95 ± 0.05
60 μM p37 S96T, N142Tc 20.8 ± 2.3
60 μM p39 S96T, N142Td NDe
60 μM p41 S96T, N142Tf 56.0 ± 0.8
60 μM p50 S96T, N142Tg NDe
a The mean IC50 values and standard error of mean were determined from at
least two replicate experiments.
b Sequencing (both direct PCR sequencing and sequence of 10 molecular
clones) spanned amino acid residues 1–591.
c Direct PCR sequencing analysis spanned amino acid residues 1–330 of the
NS5B polymerase.
d Sequencing (both direct PCR sequencing and sequence of 30 molecular
clones) spanned amino acid residues 1–591.
e ND, not determined.
f Direct PCR sequencing spanned amino acid residues 1–236 of the NS5B
polymerase.
g Direct PCR sequencing spanned amino acid residues 1–591.
Fig. 6. Amino acid substitution S96T alone or in combination with N142T
confers resistance to R1479, but not amino acid substitution N142T alone.
Relative reduction of luciferase activity in cured Huh-7 cells transiently
transfected with WT (∘) or S96T (△), N142T (□), S96T/N142T (▴) HCV
replicon RNAs. Cells were incubated for 72 h with R1479. Data points are mean
values, and error bars are SEM values calculated from at least 4 independent
experiments.
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passage 39 treated cells showed that amino acid substitutions
S96T and N142T co-existed in 22 out of the 30 clones (73.3%).
Single amino acid substitution S96T was observed in three
clones (10%), whereas single amino acid substitution N142T
was observed in one clone (3.3%). Four clones (13.2%)
contained wild type residues at these two positions.
To determine the role of the observed NS5B amino acid
substitutions, either the single amino acid substitutions S96T,
N142T or the double amino acid substitution S96T/N142T
were engineered into the transient GT 1b Con1 replicon by
site-directed mutagenesis. The level of replication and
sensitivity to R1479 and to 2′-C-Me-C were determined
(Table 9, Fig. 6). Mutant replicon S96T showed very low
replication capacity (4% compared to the wild type), whereas
single mutant N142T showed replication levels similar to the
wild type. Double mutant S96T/N142T also showed a low
level of replication (5%) compared to the wild type Con1
transient replicon, similar to that of single mutant S96T
(Table 9). The mean IC50 value for R1479 using the wild type
transient Con1 replicon was 1.96 ± 0.14 μM. A 4- to 5-fold
reduction in sensitivity to R1479 (but not to 2′-C-Me-C) was
observed for mutant S96T and for double mutant S96T/
N142T with IC50 values of 8.2 ± 0.66 μM and 10.4 ± 1.4 μM
respectively. No change in sensitivity to R1479 was observedTable 9
Resistance profile for R1479 shows lack of cross resistance to 2′-C-Me-C
Transient
replicon
Replication
levela
IC50 (μM)
b
R1479 2′-C-Me-C
WT 1 1.96 ± 0.14 1.05 ± 0.09
S96T 0.04 8.2 ± 0.66 1.28 ± 0.21
N142T 1.4 1.35 ± 0.08 0.74 ± 0.02
S96T/N142T 0.05 10.4 ± 1.40 1.6 ± 0.30
a Replication level of mutant transient replicons are expressed compared to the
WT transient replicon in the absence of inhibitor.
b The mean IC50 values and standard error of mean were determined from at
least 4 independent experiments.for mutant N142T compared to the wild type transient
replicon (Table 9).
Discussion
HCV genotypes 1a and 1b are the most prevalent worldwide
and the most difficult to treat with the current therapy (Fried et al.,
2002; Hadziyannis et al., 2004; Manns et al., 2001; Simmonds,
2004). This highlights the importance of developing new antiviral
compounds able to target different genotypes. In this study, we
have characterized and demonstrated for the first time that 2′-C-
Me-C is a potent inhibitor of genotype 1b and genotype 1a RNA
HCV replicon replication, both of laboratory optimized and of
replicons containing the NS5B derived from clinical isolates. NM-
283, a prodrug of 2′-C-Me-C, is currently in phase II clinical
development for the treatment of chronic hepatitis C. Given the
limited efficacy of the current treatment, especially for individuals
infected with a genotype 1 virus, IFN-α therapy in combination
with new inhibitors targeting the virus is likely to ensure a more
successful outcome for patients. To that effect, we demonstrated
that 2′-C-Me-C in combination with IFN-α inhibits replicon rep-
lication in an additive manner. Therefore, the use of 2′-C-Me-C
with IFN-α could be an adequate combination for a successful
outcome for infected patients. Interestingly, upon prolonged ex-
posure to high concentrations of 2′-C-Me-C, replicon RNA repli-
cation in stably transfected Huh-7 cells was reduced to such level
that the cells were no longer able to proliferate in the presence of
neomycin selective pressure. Very low levels of replicon RNA
were observed after day 8 that could be due to the detection of
residual RNAs that are not fully replication competent or due to a
small level of replicons able to replicate in the presence of
inhibitor. However, prolonged and stable replication of the HCV
subgenomic RNA replicon was not observed after adding a low
concentration of neomycin in the culture medium, suggesting that
even if the observed modest rebound observed at day 13 was due
to the detection of active replicating replicons, it was not sufficient
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studies using non-nucleoside inhibitors such as benzothiadiazines
or thiophene-2-carboxylic acid derivatives, the replicon was not
cleared from the transfected Huh-7 cells, but rather drug-resistant
replicon variants were selected (Le Pogam et al., unpublished
results). These results suggest an increased difficulty in the selec-
tion of replicon variants resistant to 2′-C-Me-C compared to non-
nucleoside polymerase inhibitors. Despite these findings and after
prolonged exposure to increasing concentrations of 2′-C-Me-C,
replicons highly resistant to 2′-C-Me-C, containing amino acid
substitution S282T in the NS5B coding region, were selected and
replicated to similar levels as the WT replicon. This amino acid
substitution was first selected in the presence of 2′-C-Me-A and
characterized by Migliaccio et al. (2003). The mechanism of
resistance to 2′-C-Me nucleosides was shown to occur through the
reduced affinity of the mutant enzyme for the inhibitor (Migliaccio
et al., 2003). Interestingly transient HCV replicons containing
S282T mutant polymerase showed a reduced replication capacity
compared to theWT transient replicon, in agreement with previous
reports (Ludmerer et al., 2005; Migliaccio et al., 2003). This
discrepancy could be due to compensatory mutations in the NS5B
protein or in other non-structural proteins. Indeed, two of the
clones described in this study contained mutations S282T in
combination with either T81P or M573R. A recent study using a
transient replicon system to characterize activity from replicons
containing NS5B from clinical isolates has shown that the
introduction of the S282T mutation in those NS5B genes inhibited
dramatically their level of replication, demonstrating that none of
the tested NS5B polymerases carried intrinsic compensatory
mutations (Ludmerer et al., 2005). Interestingly, mutation at
residue T81 was observed among the analyzed samples, whereas
residue M573 was conserved among them. Our data show that
mutation M573R does not confer a replication advantage to the
replicon RNA either alone or in combination with S282T nor does
it confer resistance to 2′-C-Me-C. The presence of M573R in the
NS5B coding region may be due to a random selection and may
have been maintained in the quasispecies possibly due to the fact
that it replicates similarly to the wild type replicon. Characteriza-
tion of the role of other viral regions isolated from infected patients
in combination with the mutant S282T should allow a better
understanding of the replication fitness of this particular resistant
mutant and address whether its intrinsic low replication level could
be compensated for in natural isolates. In the mean time, such
compensatory mutations remain to be identified.
We have recently described a new nucleoside analog, R1479,
which is a potent HCV polymerase inhibitor and that has been
selected for further clinical development for the treatment of HCV
infection. Given that future therapies for the treatment of this
infection may involve the combination of antivirals, we inves-
tigated the possible cross-resistance between 2′-C-Me-C and
R1479. To this effect, we have shown that amino acid substitution
S282T does not affect the potency of R1479 (Klumpp et al.,
2006). Studies herein to characterize resistance toR1479 show the
selection of amino acid substitutions S96T and N142T of the
NS5B coding sequence. Amino acid substitution S96Talone or in
combination with N142Tconferred resistance to R1479 but not to
2′-C-Me-C, further confirming the lack of cross-resistance bet-ween these two inhibitors. Interestingly, most of the R1479-
resistant replicon molecular clones analyzed showed the presence
of amino acid substitutions S96Tand N142T in combination. The
replication levels of transient replicons containing either S96T or
S96Tand N142Twere very low (4% to 5% of theWT). However,
amino acid substitution N142T, which replicates at levels similar
to those of WT, did not confer resistance to R1479 nor did it
rescue the replication levels of the mutant S96T when in com-
bination. Thus, the basis for co-selection of N142T is unclear at
this point. Amino acid positions 96 and 142 are outside of the
HCV polymerase active site and may be involved in primer/tem-
plate binding (Bressanelli et al., 1999). Sequence analysis across
HCV genotypes from the public database shows a high level of
conservation for both of these amino acid residues.
In summary, we showed here that the mutation S282T can be
selected by passaging HCV replicon cells in the presence of 2′-C-
Me-C and confers resistance to 2′-C-Me-C.While mutation S282T
conferred cross-resistance to 2′-C-Me-A and to 2′-C-Me-G, as
previously reported (Migliaccio et al., 2003), it did not confer
resistance to another cytidine analog (4′-Azido-Cytidine,R1479) or
to non-nucleoside polymerase inhibitors benzothiadiazine and
thiophene-2-carboxylic acid derivatives. Indeed S282T transient
replicon showed a slight increased susceptibility toR1479 (Klumpp
et al., 2006). Likewise, amino acid substitution S96T alone or in
combination with N142Tconfers resistance to R1479 but not to 2′-
C-Me-C. These data support further investigations into the potential
clinical benefit of combinations of R1479, 2′-C-Me-C, non-
nucleoside inhibitors and IFN-α. The clinical significance of the
resistance mutations identified in this study is currently unknown,
pending sequence analysis of HCV samples from HCV-infected
individuals treated with these novel antiviral agents.
Materials and methods
Construction of plasmids
The genotype 1b Con1 and genotype 1a H77 HCV sub-
genomic replicons used in this study are based on the adapted
bicistronic HCV subgenomic replicon constructs as described
(Gu et al., 2003; Krieger et al., 2001). The genotype 1b Con1
adapted transient replicon (rep PI-luc/ET) was provided by Dr.
R. Bartenschlager (Lohmann et al., 2003).
The transient genotype 1b replicon was modified for the
cloning of NS5B clinical isolates by introducing the restriction
enzyme sites AsiSI and SacII at the extremities of the NS5B gene.
The NS5B gene from genotype 1b HCV-infected plasma was
amplified and cloned into the genotype 1b transient replicon.
The transient genotype 1a repliconwas constructed by replacing
the non-structural region of the Con1 transient replicon by the H77
sequence, except for the first 75 amino acid residues, which remain
of Con 1 origin and introducing the AsiSI site and RsrII sites at the
extremities of the NS5B gene. For better replication capacity, 3
adaptive mutations were introduced (Yi and Lemon, 2004). The
NS5B gene from genotype 1a HCV-infected plasma was amplified
and cloned into the genotype 1a transient replicon.
TheNS5B570-BK expression vector containing anN-terminal
histidine tag and a 21 amino acid deletion in theNS5BC-terminus
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Welwyn (Ma et al., 2005). NS5B570-Con1 and NS5B570-Con1-
S282T expression vectors containing an N-terminal histidine tag
and a 21 amino acid deletion in the NS5B C-terminus were
engineered. NS5B570-H77 expression vector containing a C-
terminal histidine tag and a 21 amino acid deletion in theNS5BC-
terminus was also constructed.
All site-directed mutants were obtained using the Quick
Change site-directed mutagenesis kit following manufacturers'
instructions (Stratagene, La Jolla, CA, USA) and were confirmed
by double-stranded DNA sequencing.
Compounds
Recombinant human interferon alpha-2a (ROFERON, IFN-α)
was prepared at Hoffmann–La Roche (Basel, Switzerland). Stocks
were diluted in Dulbecco's modified Eagle's medium (DMEM),
10% (v/v) fetal bovine serum (FBS) and stored at −80 °C.
Compounds 2′-C-Methyl-Cytidine (2′-C-Me-C), 2′-C-Methyl-
Adenosine (2′-C-Me-A), R1479, benzo-1, 2, 4-thiadiazine (NNI-
1) and thiophene-2-carboxylic acid (NNI-2) were synthesized in
Roche Palo Alto. 2′-C-Methyl-Cytidine-5′-triphosphate (2′-C-Me-
CTP) was synthesized by TriLink BioTechnologies, and 3′-
deoxycytidine-5′-triphosphate (3′-dCTP) was purchased from
TriLink BioTechnologies (#N-3003). Stocks of 10 mM were
prepared in 100% DMSO and stored at −20 °C.
Replicon cells, IC50 and CC50 determinations
The genotype 1b Con1 and genotype 1a H77 subgenomic
replicon cell lines expressing the renilla luciferase as a reporter
gene (cell lines 2209-23 and pRLucH771b75S/I, respectively)
were maintained in DMEM supplemented with 10% (v/v) FBS,
50U/ml penicillin G, 50μg/ml streptomycin sulphate and 0.5mg/
ml neomycin (Geneticin, Invitrogen, Carlsbad, CA) at 37 °C in a
90% humidified atmosphere of 5% CO2 (Lohmann et al., 1999).
All replicon cell lines in this study were maintained at subcon-
fluence to ensure constant levels of replicon RNA (Pietschmann
et al., 2001). The curedHuh-7 cell linewas kindly provided byDr.
R. Bartenschlager and maintained in the same medium as above
but in the absence of neomycin. Replicon cell line carrying NS5B
mutation S282T (cell line clone 16) was selected as follows: 0.7
million 2209-23 replicon cells were plated in a 15-cm dish in the
presence of neomycin and 2μMof 2′-C-Me-A (20 × IC50). A dish
without compound was set up in parallel as a control. Culture
medium was changed every 3 days and fresh 2′-C-Me-A or
DMSO dilution added to the selection and control plates, res-
pectively. After 1 week of culture, untreated and treated cells were
passaged at a 1 to 5 dilution. After 4 weeks, individual cellular
cloneswere visible on the plates that were cultured in the presence
of 2′-C-Me-A. Untreated cells were continuously passaged at a 1
to 10 dilutionwhen they reached∼95% confluency. Cell clone 16
was expanded for further characterization. Direct sequencing of
PCR products spanning the entire NS5B coding region confirmed
the presence of mutation S282T.
IC50 determinations were performed as follows: five thousand
2209-23 or three thousand pRLucH771b75S/I replicon cells wereplated in 96-well plates in a total volume of 100 μl of growth
media in DMEM containing 5% (v/v) FBS without neomycin.
Inhibitors were added 24 h post-plating in 3-fold dilutions at a
final DMSO concentration of 1% (v/v). After 3 days, cells were
harvested, and replicon reduction was measured by renilla lucif-
erase signal quantification using the renilla luciferase assay
system and following manufacturer's instructions (Promega
Madison, WI, USA) and/or by quantitative kinetic PCR deter-
mination of the levels of HCV replicon RNA. The levels of HCV
RNA were determined using the probe 5′-TCCTGCCGAGAA-
AGTATCCATCATGGCT-3′, forward 5′-GCTGCTATTGGGC-
GAAGTG-3′ and reverse 5′-GCCGCCGCATTGCA-3′ primers.
Probe and primer sets specific for β-actin were used as an endo-
genous control. All reagents for the RT-PCR were obtained from
Applied Biosystems, Foster City, CA, USA. Reactions were ana-
lyzed on a 7700 Sequence Detector (PE Biosystems). IC50 deter-
minations using transient replicons were performed as follows:
four million cured Huh-7 cells were transfected with 10 μg of in
vitro transcribed genotype 1b Con1 HCV transient subgenomic
replicon RNA (wild type or mutants) prepared as previously
described (Lohmann et al., 2003). After electroporation, cells
were resuspended in 9.6 ml of DMEM containing 5% (v/v) FBS
and plated in 48-well plate at 80,000 cells/well (in 200 μl final
volume). Inhibitors were added 24 h post-transfection in 3-fold
dilutions at a final DMSO concentration of 1% (v/v) and firefly
luciferase reporter signal was read 72 h after addition of inhibitors
using the Luciferase Assay system (Promega, Madison, WI,
USA). The IC50 values were assessed as the inhibitor concentra-
tion at which a 50% reduction in the levels of firefly luciferase
reporter was observed as compared to untreated samples. For the
characterization of clinical isolates cloned into the transient
replicons (Con1 or H77), four million cured Huh-7 cells were
transfected with 5 μg of in vitro transcribed RNA. After elec-
troporation, cells were resuspended in 7.2 ml of DMEM
containing 5% (v/v) FBS and plated in 96-well plates at 50,000
cells/well (in 100 μl final volume).
Cytotoxicity was assessed by measuring cell viability using
Cell Proliferation Reagent WST-1 (Roche Applied Science,
Indianapolis, IN, USA). Cells were incubated with inhibitors for
72 h as described above. WST-1 reagent was added 2 h before
harvesting, and cell viability measurement was performed
following manufacturer's instructions. The effect of inhibitors
on the incorporation of tritiated thymidine into cellular DNA
was measured using the Scintillation proximity [3H]-thymidine
uptake assay system (Amersham Biosciences, Piscataway, NJ,
USA) following manufacturer's instructions.
In vitro combination studies
HCV replicon 2209-23 cells were plated as described above.
Inhibitors were added at different concentrations in 3-fold dilutions
at a final DMSO concentration of 1% (v/v) in a checkerboard
fashion, including titrations of each of the compounds alone as
reference controls. The concentrations of IFN-α used ranged from
10 to 0.04 IU/ml and from 10 to 0.04 μM for 2′-C-Me-C. The
degree of interaction between two drugs was first determined using
the Elion's Fractional Inhibitory Concentration (FIC) and
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inhibitor alone and in the presence of constant concentrations of the
other were calculated based on the reduction of renilla luciferase
reporter using the Luciferase Assay system (Promega, Madison,
WI, USA). These endpoint conditions were expressed as fractions
of the IC90 for each compound alone (FIC) and used to produce
isobolograms. In this study, we have adopted the following criteria:
when the combination index (FICA + FICB) > 1, the combination is
considered antagonistic. Between 1 and 0.5, the combination is
considered additive.When it is≤0.5, the combination is considered
synergistic. The data were also examined using the Pritchard and
Shipman's 3-D model (MacSynergy II) (Prichard and Shipman,
1990), where three replicate data sets were used to produce the
theoretic additive surface and 95% confidence limits. Volumes
above or below the theoretic additive surface were determined to
indicate the degree of synergy or antagonism. Data were analyzed
using Microsoft Excel.
Replicon clearance assay
HCVreplicon cells were cultured in the presence of 8 μMof 2′-
C-Me-C and in the absence of neomycin selection for 13 days
(replicon clearance phase). Cells were passaged at a 1:3 ratio when
confluent and samples were taken for HCV RNA level deter-
mination. After 13 days, the inhibitor was removed, and cells were
cultured for a further 15 days in culture medium containing
0.25 mg/ml of neomycin. Levels of HCV RNAwere determined
using the quantitative PCR assay as described above and using the
following equations: the absolute kinetic PCR cycle threshold (Ct)
was obtained for the neomycin gene and for the endogenous control
β-actin gene at each time point. To normalize HCV replicon to the
endogenous control, dCt is calculated as dCt = (CtNeo) − (CtActin)
for each time point. The level ofHCVrepliconRNA is calculated as
log (2^((−1)*ddCT)) (comparative Ct method, Applied Biosys-
tems) where ddCt = (dCt(Day x) − dCt(Day 0)). The estimated
variability of the assay is typically 0.25 log and no more than 0.5
log. The TaqMan PCR reactions were performed in triplicate using
100 ng of total RNA. The limit of detection of the quantitative PCR
assay is determined by the PCR cycle at which the amplification
signal can be detected. The amount of HCV RNA detected after
prolonged treatment with the inhibitor (Ct: 38) is close to the limit
of detection (Ct: 40). Results were expressed as log RNA change
compared to the HCV RNA level in untreated cells at day 0.
Selection of clonal replicons resistant to 2′-C-Me-C
For the selection of replicon cellular clones resistant to 2′-C-
Me-C, 0.7 million HCV replicon 2209-23 cells were plated in a
15-cm dish in the presence of 6 μM of 2′-C-Me-C and 0.5 mg/ml
of neomycin. A dish without compound was set up in parallel as a
control. Culture medium was changed every 3 days and fresh 2′-
C-Me-C added where required. Cells were passaged at a 1 to 10
dilution twice and maintained in 6 μM for 7 weeks before
increasing the concentration of 2′-C-Me-C to 12 μM. After
2weeks, the concentration of 2′-C-Me-Cwas increased to 24μM.
Individual cellular clones were visible and picked 3 weeks later.
Untreated cells were continuously passaged at a 1 to 10 dilutionwhen they reached ∼95% confluency. Four cellular clones from
the 2′-C-Me-C treated dish were expanded for further character-
ization by direct sequencing of PCR products spanning the entire
non structural coding region and by determination of their sus-
ceptibility to the inhibitor. Sequencing reactions were carried out
on both strands using ABI 3730 ×l DNA Analyzer. Sequences
were analyzed using Sequencher and VNTI softwares. For
molecular cloning purpose, NS5B amplicons were cloned into
TOPO vector (Invitrogen, Carlsbad, CA, USA) according to
manufacturer's instructions.
Selection of replicon pools resistant to R1479
The replicon cell line 2209-23 was seeded at a density of 0.5
million cells in a T75 cm2 flask and cultured in the presence of
0.5 mg/ml of neomycin and of increasing concentrations of
R1479, starting at 1 μM and up to 60 μM. Cells were passaged
at a 1 to 3 dilution when 95% confluency was reached. A
parallel flask of 2209-23 cells was passaged without inhibitor as
a control. Culture medium was changed every 3 days and fresh
compound added where required. Replicon cells were charac-
terized by determining their sensitivity to R1479 and by direct
sequencing of PCR products spanning the entire NS5B coding
region.
HCV polymerase assay
The inhibition potency of 2′-C-Me-CTP on the RNA-
dependent RNA polymerase (RdRp) activity of recombinant
NS5B570-BK, NS5B570-Con1 and NS5B570-H77 proteins
was measured as the incorporation of radiolabeled nucleotide
monophosphate into acid-insoluble RNA products. The method
was used as previously described (Ma et al., 2005) with some
modifications, using either cIRES RNA template (genotype 1a
assay conditions) or Poly I RNA template (PI assay conditions).
Briefly, IC50 determinations, measured under genotype 1a assay
conditions, were carried out using 200 nM of in vitro transcribed
cIRES RNA template derived from the 3′ end of the negative
strand RNA genome (Smith et al., 2002), 1 μCi of tritiated UTP
(42 Ci/mmol), 1 mM ATP, 1 mM GTP, 1 μM CTP, 1× TMDN
buffer (40 mM Tris–HCl pH 8.0, 4 mM MgCl2, 4 mM DTT,
40 mM NaCl) and 200 nM enzyme. The IC50 determinations
measured under PI assay conditions contained 8 μg/ml Poly I
RNA (Yamasa Co.), 4 μg/ml oligo C16 (Dharmacon), 1 μCi of
titrated CTP (25 Ci/mmol, corresponding to a final CTP con-
centration of 0.8 μM), 1× TMDN buffer and 200 nM enzyme. In
both assay conditions, 5μl of serially diluted inhibitor was added
to each reaction. The inhibition potency of 2′-C-Me-CTP on the
RdRp activity of NS5B570-Con1-S282Twas determined under
genotype 1b assay conditions as previously described (Klumpp
et al., 2006) with the following modifications: each reaction
mixture contained 200 nM cIRES RNA template, 1μCi of
tritiated UTP (42 Ci/mmol), and 1× TMDN buffer. NS5B570-
BK and NS5B570-Con1 enzymes were used as controls and
tested under the same assay conditions. The final reaction vol-
ume was 50 μl under all assay conditions. All reactions con-
tained a final 10% DMSO.
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Preparation of membrane-associated cytoplasmic replicase
complexes (CRC) from replicon cells was described previously
(Ma et al., 2005). In vitro replicase assay and RNA product
analysis were performed as previously described except that 5 μl
of sCRC (2.5 × 106 cell equivalent) was used in the reactions (Ma
et al., 2005). RNA synthesis activity of the replicase complex in
the presence of inhibitor was expressed as a percentage of the
RNA synthesis activity in the absence of inhibitor. The IC50 value
was determined by GraphPad Prism software using the four
parameter logistic equation Y = %Min + (%Max − %Min)/
(1 + 10^(logIC50 − X)*Hillslope), in which “Y” corresponds to
the relative enzyme activity (in%), “%Min” is the residual relative
enzymatic activity at the highest compound concentration, “%
Max” is the relative enzymatic activity at the lowest compound
concentration, X is the logarithm of inhibitor concentration.
Western blotting detection of NS5B
Serial dilutions of the recombinant NS5B570-BK and mem-
brane fractions from replicon cells were resolved by SDS-PAGE
and transferred to PVDF membranes. The membranes were
probedwith a rabbit antiserum developed against NS5B570-BK.
The Western blotting detection was performed using a horse
peroxidase conjugated goat anti-rabbit IgG secondary antibody
(Santa Cruz Biotechnologies #SC-2030) and ECLplus substrate
(AmershamBiosciences #RPN2132). Chemifluorescence signal
detection was performed using a Typhoon 9400 scanner
(Amersham Biosciences) and density volumes of NS5B bands
quantified using ImageQuant software.
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